Lung Injury - Pipeline Review, H2 2011

Global Markets Direct, November 2011, Pages: 74

Lung Injury - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Lung Injury - Pipeline Review, H2 2011', provides an overview of the Lung Injury therapeutic pipeline. This report provides information on the therapeutic development for Lung Injury, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Lung Injury. 'Lung Injury - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Lung Injury.
- A review of the Lung Injury products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Lung Injury pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Lung Injury.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Lung Injury pipeline depth and focus of Lung Injury therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Lung Injury Therapeutic Products under Development, Key Players in Lung Injury Therapeutics, Lung Injury Pipeline Overview, Lung Injury Pipeline, Lung Injury Pipeline Assessment

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Lung Injury Overview
Therapeutics Development
An Overview of Pipeline Products for Lung Injury
Lung Injury Therapeutics under Development by Companies
Lung Injury Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Lung Injury Therapeutics - Products under Development by Companies
Lung Injury Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Lung Injury Therapeutics Development
GlaxoSmithKline plc
Quark Pharmaceuticals, Inc.
Novartis AG
Discovery Laboratories, Inc.
Silence Therapeutics plc.
Advanced Life Sciences Holdings, Inc.
REVOTAR Biopharmaceuticals AG
Altor BioScience Corporation
Angion Biomedica Corp.
NovImmune SA
KYORIN Pharmaceutical Co., Ltd.
Faron Pharmaceuticals, Ltd.
Lung Injury - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ALS-886 - Drug Profile
NI-0101 - Drug Profile
SB681323 - Drug Profile
Aerosurf - Drug Profile
BB3 - Drug Profile
ALT-836 - Drug Profile
Respiratory And Inflammatory Diseases Program - Drug Profile
Bimosiamose - Drug Profile
KRP-109 - Drug Profile
N-Acetyl Cysteine - Drug Profile
Calfactant - Drug Profile
Calfactant - Drug Profile
Human albumin - Drug Profile
Hetastarch - Drug Profile
Atu111 - Drug Profile
FP-1201 - Drug Profile
GM-CSF - Drug Profile
5% Human Albumin - Drug Profile
N-acetylcysteine - Drug Profile
Rosuvastatin - Drug Profile
Atu134 - Drug Profile
TOBI Podhaler - Drug Profile
Methylprednisolone - Drug Profile
Ulinastatin - Drug Profile
Furosemide + Albumin + Norepinephrine + Vasopressin + Phenylephrine + Epinephrine + Dobutamine - Drug Profile
Lung Injury Therapeutics – Drug Profile Updates
Lung Injury Therapeutics - Discontinued Products
Lung Injury - Featured News
Nov 08, 2011: Silence Provides Development Update Of Atu134
Oct 25, 2011: APEPTICO Successfully Completes Phase I Trial With AP301 In Oedematous Respiratory Failure
Oct 07, 2011: Faron Completes Phase I/II Clinical Trial With FP-1201 In Acute Lung Injuries
Jul 19, 2011: P2D Bioscience Receives NIH Funding To Develop Drugs For Lung Disease
Jun 01, 2011: BARDA Funds Development Of Drug To Prevent Radiation Lung Injury
May 23, 2011: Altor BioScience Receives $3m SBIR Phase II Competing Renewal Grant From NHLBI
May 09, 2011: Faron Reports Positive Headline Data From FPCLI001 Clinical Study With FP-1201 In Acute Lung Injuries
Apr 20, 2011: Discovery Labs’s KL4 Surfactant Aerosolization Program Data To Be Presented At Pediatric Academic Societies Annual Meeting
Apr 12, 2011: Faron Completes Recruitment For Phase I/II Clinical Trial Of FP-1201
Sep 16, 2010: Faron's Lead Product FP-1201 Enters Next Phase Of Study
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Lung Injury, H2 2011
Products under Development for Lung Injury – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
GlaxoSmithKline plc, H2 2011
Quark Pharmaceuticals, Inc., H2 2011
Novartis AG, H2 2011
Discovery Laboratories, Inc., H2 2011
Silence Therapeutics plc., H2 2011
Advanced Life Sciences Holdings, Inc., H2 2011
REVOTAR Biopharmaceuticals AG, H2 2011
Altor BioScience Corporation, H2 2011
Angion Biomedica Corp., H2 2011
NovImmune SA, H2 2011
KYORIN Pharmaceutical Co., Ltd., H2 2011
Faron Pharmaceuticals, Ltd., H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Lung Injury Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Lung Injury, H2 2011
Products under Development for Lung Injury – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Discovery and Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Customers who bought this item also bought

• Lung Injury - Pipeline Review, H2 2012
• Acute Lung Injury - Pipeline Review, H2 2012
• Acute Respiratory Distress Syndrome - Pipeline Review, H2 2012
• Lung Injury - Pipeline Review, H1 2012
• Acute Lung Injury - Pipeline Review, H1 2012
• Optic Nerve Injury - Pipeline Review, H2 2012
• Lung Adenocarcinoma - Pipeline Review, H2 2012
• Lung Disease - Pipeline Review, H2 2012
• Acute Pain - Pipeline Review, H2 2012
• Lung Infections - Pipeline Review, H2 2012